<DOC>
	<DOCNO>NCT02026947</DOCNO>
	<brief_summary>The aim study investigate whether sodium benzoate superior placebo decrease symptom among patient attenuated/transient psychosis . A total 140 patient randomize 1:1 ratio receive sodium benzoate 1 g/day placebo 12 week . Concerning statistical power , number patient sufficient obtain statistical significance clinically meaningful effect size 0.40 ( Cohen 's ) . The primary outcome measure change PANSS sum score delusion , hallucination , suspiciousness conceptual disorganization ( PANSS item inclusion criterion ) week 12 . Change CGI score week 12 primary outcome measure . The secondary outcome measure change PANSS total score week 12 , CGI score week 24 , GAF week 12 24 .</brief_summary>
	<brief_title>Sodium Benzoate Treatment Attenuated/Transient Psychosis . A Randomized Placebo-controlled Trial .</brief_title>
	<detailed_description>Early treatment psychotic disorder result well outcome , several small randomize control trial ( RCTs ) indicate pharmacological treatment prodromal patient subthreshold psychosis might prevent transition psychotic disorder . Use risperidone statistically significant effect 6 month , 12 month , olanzapine show beneficial trend . The use antipsychotic prevention psychosis controversial due adverse effect , therefore , use better-tolerated agent natural compound like benzoid acid omega fatty acid might promise approach . Glutamatergic hypothesis gain increase support explain symptom schizophrenia , hypofunction N-methyl-D-aspartate ( NMDA ) receptor consider nowadays major factor pathophysiology disease . Several NMDA-enhancing agent glycine , D-alanine , D-serine , sarcosine bitopertin show beneficial effect add-on treatment antipsychotic . D-amino acid oxidase ( DAAO ) metabolize D-alanine D-serine , co-agonists NMDA-receptor , , therefore , decrease DAAO activity result enhancement NMDA-receptor function . Recently , randomize control trial 52 patient chronic schizophrenia well tolerate show robust beneficial effect DAAO inhibitor sodium benzoate ( 1 g/d ) compare placebo ( effect size 1.76 PANSS total score ; Tsai et al . 2012 ) . The aim study investigate whether sodium benzoate superior placebo decrease symptom among patient attenuated/transient psychosis . A total 140 patient randomize 1:1 ratio receive sodium benzoate 1 g/day placebo 12 week . Concerning statistical power , number patient sufficient obtain statistical significance clinically meaningful effect size 0.40 ( Cohen 's ) . The primary outcome measure change PANSS sum score delusion , hallucination , suspiciousness conceptual disorganization ( PANSS item inclusion criterion ) week 12 . Change CGI score week 12 primary outcome measure . The secondary outcome measure change PANSS total score week 12 , CGI score week 24 , GAF week 12 24 . An interim analysis do obtain result first 40 patient . If effect size ( Cohen 's ) primary outcome measure less 0.30 , study stop prematurely .</detailed_description>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Sodium Benzoate</mesh_term>
	<criteria>Age 15 30 year Meet least 1 criterion either follow group : Group a. Attenuated Psychotic Symptoms : Symptom score 3 PANSS delusion scale , 23 PANSS hallucination scale , 34 PANSS suspiciousness , 34 PANSS conceptual disorganization scale ( frequency symptom ≥ 2 times/wk period least 1 week longer 5 year , occur within last year ) Group b . Transient Psychosis : Symptoms score ≥ 4 PANSS hallucination scale , ≥ 4 PANSS delusion scale , ≥ 5 PANSS conceptual disorganization scale ( symptom sustain beyond week resolve without antipsychotic medication within last year ) history previous psychotic disorder manic episode ( treat untreated ) ; substanceinduced psychotic disorder ; acute suicidal aggressive behavior ; current DSMIV diagnosis substance dependence ( except cannabis dependence ) ; neurological disorder ( e.g. , epilepsy ) ; IQ le 70 ( diagnosis mental retardation verify school performance ) ; previous treatment antipsychotic moodstabilizing agent ( &gt; 1 week ) ; pregnancy inadequate pregnancy prevention among sexually active female , history allergy severe adverse event sodium benzoate ; laboratory value 10 % outside normal range transaminase , thyroid hormone , Creactive protein ; another severe intercurrent illness may put person risk influence result trial affected ability take part trial . Use benzodiazepinederivatives allow trial .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>April 2014</verification_date>
</DOC>